Modella AI has signed a multi-year agreement with AstraZeneca for expediting AI-driven oncology clinical development.

The approval comes amid speculation that AstraZeneca CEO Pascal Soriot is considering delisting its UK stock market listing for the US.

Clinical trials have demonstrated that both biosimilars match the reference product's quality, safety and efficacy standards.

The U.S. Food and Drug Administration has approved Regeneron Pharmaceuticals' Lynozyfic, a therapy for recurrent multiple myeloma, boosting the company's shares by 2%.

Regeneron Pharmaceuticals gains FDA approval for Lynozyfic drug targeting multiple myeloma, with launch details and executive ...

Prescient Therapeutics (ASX: PTX), a clinical-stage oncology company, is making strides in the treatment of cutaneous T-cell ...

A patient shares how an event about clinical trials at Moores Cancer Center brought a community together to educate and ...

When surgeons dissect tissue to remove a tumor or make a repair, they must work cautiously, relying on electrophysical ...

Patients with rare diseases are increasingly working to find and fund their own cures. But should they have to?

The law, slated to take effect in September, requires health plans to cover the treatment given by in-network providers, not ...

Shares of Liminatus Pharma rose after the company shared plans to collaborate on developing a diagnostic kit for detecting pancreatic cancer. The stock advanced 3.7%, to $9.35, in after-hours trading ...